Other headlines:Naviscan signs Korean distributor IT sales rise at Infinitt
Philips Healthcare has introduced to U.S. customers MammoDiagnost VU, a stand-alone mammography workstation that enables multivendor and multimodality image management and integration. Already available in Europe, the MammoDiagnost VU simplifies use by streamlining labor-intensive steps, automating breast tissue alignment for digital mammograms, and supporting personalized work lists.
Naviscan has signed a distribution agreement with the Hae Dong company to market and service breast-specific PET scanners in the Republic of South Korea. The first such unit capable of positron emission mammography will be installed at Seoul National University Hospital, where it will be available to physicians and researchers while awaiting Korean regulatory approval. The scanner uses PET technology to produce tomographic images that visualize breast tumors down to 2 mm, which is about the width of a grain of rice. About the size of an x-ray mammography unit, the PET scanner uses gentle breast immobilization to reduce motion artifact and improve image resolution.
Web-based IT vendor Infinitt North America is on track for a record year. The company reports that product sales in the U.S. during the first two quarters of 2009 have exceeded those of any two consecutive quarters in the firm's history. Its performance is all the more significant, according to company execs, given tight budgets at hospitals in this country and uncertainty about the future direction of healthcare. Infinitt offers web-based RIS and PACS products that support radiology, cardiology, mammography, and advanced visualization on a single common database.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.